Translating Breakthroughs in RSV Vaccine Science Into Care for Older Adults (Enduring from 23LV231)
CE Information
1.75 CE credits (0.4 pharmacology)Completion Time
1 hour, 45 minutesAvailable Until
November 12, 2024Posted By
Prime CENavigate
Overview
Specialties
GerontologicalSubspecialties
Infectious Disease and Primary CareClinical Topics
Geriatric Medicine, Infectious Disease, and Primary CareIntended Audience: Infectious diseases specialists and their interprofessional teams of NPs, PAs, nurses and pharmacists
Decades of work have led to exciting new developments in respiratory syncytial virus (RSV) prevention, with the first-ever vaccines against RSV recently approved for use in older adults. Get ready to support implementation of these novel prevention strategies in your practice by tuning in to this enduring accredited video from IDWeek 2023, where a renowned panel of experts in RSV and vaccine science discuss:
- Impacts of RSV on the aging population and the healthcare system
- The science behind new and emerging vaccines to prevent RSV
- Real-world, evidence-based strategies to engage older adults in shared decision-making about RSV vaccination
Speakers
Professor of Medicine, Epidemiology, and Global Health
Division of Allergy & Infectious Diseases
University of Washington
Seattle, WA
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, NY
David S Greer Professor of Geriatrics
Director, Division of Geriatrics and Palliative Medicine
Professor, Health Services Policy and Practice
Warren Alpert Medical School of Brown University
Associate Director, Center on Innovation in Long-Term Services a
CE Information
This activity offers 1.75 CE credits (0.4 pharmacology) to attendees.
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.75 contact hours (which includes 0.4 hour of pharmacology).
Disclosures
*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.
The following individuals have identified relevant financial relationships with ineligible companies to disclose:
-
Helen Chu, MD, MPH (Speaker)
Advisory Board or Panel – AbbVie, Merck, VirThe relationships reported above are related to the following therapeutic area: Infectious Disease
Speakers Bureau or other Promotional Education – Catalyst CME, Clinical Care Options CME, Medscape CME, Vindico CME -
Angela Branche, MD (Speaker)
Advisory Board or Panel – NovavaxThe relationships reported above are related to the following therapeutic area: Infectious Disease
Consultant – GlaxoSmithKline, Moderna
Grants / Research Support – Cyanvac, Moderna, Novavax, Vaccine.com -
Stefan Gravenstein, MD, MPH (Speaker)
Advisory Board or Panel – Genentech, GlaxoSmithKline, Janssen, Moderna, Novavax, PfizerThe relationships reported above are related to the following therapeutic area: Vaccines
Consultant – Genentech, GlaxoSmithKline, Janssen, Merck, Moderna, Novavax, Pfizer, Reviral, Seqirus
Grants / Research Support – Genentech, Moderna, Pfizer, Sanofi, Seqirus
Speakers Bureau or other Promotional Education – GlaxoSmithKline, Janssen, Moderna, Pfizer, Sanofi, Seqirus
The following individuals have no relevant financial relationships with ineligible companies to disclose:
- Michael R Stinchon, Jr, RPh (Moderator)
- Ricardo Correa, MD, EdD, FACP, FACE, FAPCR, FACMQ (Reviewer)
- Gabriela Andonie, PharmD, BCIDP, AAHIVP (Planner)
- Lisa Wakefield, MSN, APRN, FNP-BC (Planner)
All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.
Log in and start activity